LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
Aditya Bardia, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Hope S. Rugo, Adam Brufsky, Kevin Kalinsky, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Lisa A. Carey, L. Gianni, Martine Piccart, Sibylle Loibl, D M Goldenberg, Q. Hong, Martin Olivo, Loretta M. Itri, Sara A. Hurvitz
Topics & Concepts
MedicineClinical endpointInternal medicineEribulinTriple-negative breast cancerPopulationOncologyGemcitabineMetastatic breast cancerTaxanePhases of clinical researchVinorelbineIrinotecanBreast cancerProgression-free survivalCancerRandomized controlled trialChemotherapyColorectal cancerCisplatinEnvironmental healthCancer Treatment and PharmacologyHER2/EGFR in Cancer ResearchAdvanced Breast Cancer Therapies